Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
Completed · Phase 2
Conditions studied: Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
In brief
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining vaccine therapy, sargramostim, and interleukin-2 may kill more cancer cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy, sargramostim, and interleukin-2 in treating patients who have advanced tumors.
Key facts
- Study ID
- NCT00003125
- Run by
- Georgetown University
- People needed
- 24
- Starts
- 1998-01-01
- Expected to finish
- 2004-11-01
- Last updated by the study team
- 2011-03-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Lombardi Cancer Center, Georgetown University — Washington D.C., District of Columbia, United States
- National Naval Medical Center — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.